Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • bimekizumab-bkzx

    - PMLiVE

    UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome

    The study demonstrated a sustained reduction in seizures for patients

    - PMLiVE

    Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

    Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

    - PMLiVE

    UCB shares promising results for fenfluramine in ultra-rare form of epilepsy

    CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births

    - PMLiVE

    UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials

    Approximately 125 million people worldwide are affected by some form of psoriasis

    - PMLiVE

    J&J/Protagonist’s icotrokinra shows promise in difficult-to-treat plaque psoriasis

    An estimated eight million people in the US are living with the immune-mediated skin disease

    - PMLiVE

    J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme

    More than 125 million people worldwide are estimated to be living with the immune-mediated skin disease

    - PMLiVE

    Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis

    Plaque psoriasis affects up to 90% of patients with the immune-mediated disease

    - PMLiVE

    J&J and Protagonist share promising phase 3 results for icotrokinra in plaque psoriasis

    More than 125 million people globally are estimated to be living with the skin disorder

    - PMLiVE

    UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults

    The inflammatory skin disease affects approximately one in every 100 people in the US

    - PMLiVE

    UCB shares ‘encouraging’ data for Alzheimer’s disease candidate bepranemab

    The drug showed benefits across key secondary endpoints, including tau accumulation

    - PMLiVE

    Dermavant reports positive long-term results for Vtama cream in atopic dermatitis

    More than 26 million people in the US are affected by the inflammatory skin condition

    - PMLiVE

    Johnson & Johnson’s Tremfya shows promise in ‘special site’ plaque psoriasis

    The immune-mediated disease affects more than 125 million people worldwide

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links